<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ records, physical examination and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein (<italic>p</italic> = 0.045), and increased vascular endothelial growth factor (<italic>p</italic> = 0.004) and epidermal growth factor (<italic>p</italic> = 0.009). A multivariate analysis identified total cholesterol (<italic>p</italic> = 0.027) and vascular endothelial growth factor (<italic>p</italic> = 0.011) to be independently associated with rosuvastatin treatment. Given beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.</p>
</abstract>

Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ records, physical examination and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein (p = 0.045), and increased vascular endothelial growth factor (p = 0.004) and epidermal growth factor (p = 0.009). A multivariate analysis identified total cholesterol (p = 0.027) and vascular endothelial growth factor (p = 0.011) to be independently associated with rosuvastatin treatment. Given beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

University Ss Cyril and Methodius Faculty of Pharmacy

University Ss Cyril and Methodius Faculty of Medicine

Acta Pharmaceutica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the...

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

Article Category: Short communication

Pubblicato online: 30 dic 2021

Pagine: 303 - 315

Accettato: 21 giu 2021

DOI: https://doi.org/10.2478/acph-2022-0018

Parole chiave
rosuvastatin, vascular endothelial growth factor, epidermal growth factor, cardiovascular risk

© 2022 Ana Vavlukis., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

Article Category: Short communication

Pubblicato online: 30 dic 2021

Pagine: 303 - 315

Accettato: 21 giu 2021

DOI: https://doi.org/10.2478/acph-2022-0018

Parole chiaverosuvastatin, vascular endothelial growth factor, epidermal growth factor, cardiovascular risk

© 2022 Ana Vavlukis., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Parole chiave
rosuvastatin, vascular endothelial growth factor, epidermal growth factor, cardiovascular risk